Bao Suxia, Zhao Qiang, Zheng Jianming, Li Ning, Huang Chong, Chen Mingquan, Cheng Qi, Zhu Mengqi, Yu Kangkang, Liu Chenghai, Shi Guangfeng
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
Institute of Liver Diseases, Dawn Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200040, China.
Int Immunopharmacol. 2017 May;46:97-104. doi: 10.1016/j.intimp.2017.03.001. Epub 2017 Mar 7.
Interleukin-23 (IL-23) is required for T helper 17 (Th17) cell responses and IL-17 production in hepatitis B virus infection. A previous study showed that the IL-23/IL-17 axis aggravates immune injury in patients with chronic hepatitis B virus infection. However, the role of IL-23 in acute liver injury remains unclear.
The purpose of this study was to determine the role of the inflammatory cytokine IL-23 in lipopolysaccharide/d-galactosamine (LPS/GalN)-induced acute liver injury in mice.
Serum IL-23 from patients with chronic hepatitis B virus (CHB), acute-on-chronic liver failure (ACLF) and healthy individuals who served as healthy controls (HCs) was measured by ELISA. An IL-23p19 neutralizing antibody or an IL-23p40 neutralizing antibody was administered intravenously at the time of challenge with LPS (10μg/kg) and GalN (400mg/kg) in C57BL/6 mice. Hepatic pathology and the expression of Th17-related cytokines, including IL-17 and TNF-α; neutrophil chemoattractants, including Cxcl1, Cxcl2, Cxcl9, and Cxcl10; and the stabilization factor Csf3 were assessed in liver tissue.
Serum IL-23 was significantly upregulated in ACLF patients compared with CHB patients and HCs (P<0.05 for both). Serum IL-23 was significantly upregulated in the non-survival group compared with the survival group of ACLF patients, which was consistent with LPS/GalN-induced acute hepatic injury in mice (P<0.05 for both). Moreover, after treatment, serum IL-23 was downregulated in the survival group of ACLF patients (P<0.001). Compared with LPS/GalN mice, mice treated with either an IL-23p19 neutralizing antibody or an IL-23p40 neutralizing antibody showed less severe liver tissue histopathology and significant reductions in the expression of Th17-related inflammatory cytokine, including IL-17 and TNF-α; neutrophil chemoattractants, including Cxcl1, Cxcl2, Cxcl9, and Cxcl10; and stabilization factors Csf3 within the liver tissue compared with LPS/GalN mice (P<0.05 for all).
High serum IL-23 was associated with mortality in ACLF patients and LPS/GalN-induced acute liver injury in mice. IL-23 neutralizing antibodies attenuated liver injury by reducing the expression of Th17-related inflammatory cytokines, neutrophil chemoattractants and stabilization factors within the liver tissue, which indicated that IL-23 likely functions upstream of Th17-related cytokine and chemokine expression to recruit inflammatory cells into the liver.
白细胞介素-23(IL-23)是乙肝病毒感染中辅助性T细胞17(Th17)细胞反应及IL-17产生所必需的。先前一项研究表明,IL-23/IL-17轴会加重慢性乙肝病毒感染患者的免疫损伤。然而,IL-23在急性肝损伤中的作用仍不清楚。
本研究旨在确定炎性细胞因子IL-23在脂多糖/d-半乳糖胺(LPS/GalN)诱导的小鼠急性肝损伤中的作用。
采用酶联免疫吸附测定法(ELISA)检测慢性乙肝病毒(CHB)患者、慢加急性肝衰竭(ACLF)患者及作为健康对照(HCs)的健康个体血清中的IL-23。在C57BL/6小鼠用LPS(10μg/kg)和GalN(400mg/kg)攻击时,静脉注射IL-23p19中和抗体或IL-23p40中和抗体。评估肝组织病理学以及Th17相关细胞因子(包括IL-17和TNF-α)、中性粒细胞趋化因子(包括Cxcl1、Cxcl2、Cxcl9和Cxcl10)和稳定因子Csf3的表达。
与CHB患者和HCs相比,ACLF患者血清IL-23显著上调(两者P均<0.05)。与ACLF患者存活组相比,非存活组血清IL-23显著上调,这与LPS/GalN诱导的小鼠急性肝损伤一致(两者P均<0.05)。此外,治疗后,ACLF患者存活组血清IL-23下调(P<0.001)。与LPS/GalN小鼠相比,用IL-23p19中和抗体或IL-23p40中和抗体治疗的小鼠肝组织组织病理学较轻,肝组织中Th17相关炎性细胞因子(包括IL-17和TNF-α)、中性粒细胞趋化因子(包括Cxcl1、Cxcl2、Cxcl9和Cxcl10)和稳定因子Csf3的表达显著降低(所有P均<0.05)。
高血清IL-23与ACLF患者的死亡率及LPS/GalN诱导的小鼠急性肝损伤相关。IL-23中和抗体通过降低肝组织中Th17相关炎性细胞因子、中性粒细胞趋化因子和稳定因子的表达减轻肝损伤,这表明IL-23可能在Th17相关细胞因子和趋化因子表达的上游发挥作用,将炎性细胞募集到肝脏。